Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization
- Institution
- Seattle Children's Hospital, WA
- Principal investigator
- Kenneth D Stuart
- Funding
- $2.1M
- Duration
- 2017–2027
Moonbase score
Still being scored
Abstract
ABSTRACT (Overall) Malaria, HIV/AIDS, and Covid are three of the most devastating infectious diseases, impacting millions of people world-wide. Effective vaccines against the pathogens that cause these diseases (HIV, SARS-CoV-2 and Plasmodium falciparum) have proven elusive and/or affected by pathogen variation and thus traditional vaccine approaches are unlikely to succeed in eradicating these diseases. In addition to our limited understanding of the desired immune responses to confer protection against the pathogens and our limited ability to elicit such responses, vaccine efficacy is also confounded by the diversity of pathogens, human populations, environmental exposures, and health status. The projects described herein are designed to support the identification of immune profiles that correlate with vaccine efficacy and are of potential relevance to protection against HIV-1, SARS CoV-2 and P. falciparum infection. Beyond the importance of combatting these diseases, the strategies for profiling immunity in response to infection and vaccination hold promise for garnering fundamental insights into the complexity of the human immune system. Such insights have the potential to impact strategies for vaccine development and for producing new therapies for many diseases.
Research team
- Margaret Juliana McelrathPI
- Kenneth D StuartPI
- Troy R TorgersonPI
LOADING MOONBASE SCORE
Questions for Seattle Children's Hospital
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California, San FranciscoNot yet scored
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
Christopher Craig Dvorak · $21K · 2025–2029
- NIH · University of California, San FranciscoNot yet scored
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
Christopher Craig Dvorak · $1.7M · 2024–2029
- NIH · Seattle Children's HospitalNot yet scored
Collective Responses to Malaria Vaccination
Kenneth D Stuart · $679K · 2022–2027